Eliglustat is a medication designed for the treatment of Gaucher disease type 1, a genetic disorder characterized by the accumulation of glucocerebroside due to a deficiency in the enzyme glucocerebrosidase. It is a synthetic compound that inhibits the glucocerebrosidase enzyme’s activity, thus reducing the buildup of harmful substrates in the lysosomes. Eliglustat is available in capsules, with a typical dosage of 84 mg per capsule.

The drug is considered bioequivalent and therapeutically equivalent to the reference product Cerdelga, developed by Genzyme Corporation. As of the date of the document, Eliglustat has achieved tentative approval by the U.S. FDA for the treatment of this condition, pending resolution of patent-related issues. The tentative approval is contingent upon the expiration of certain patents and the outcome of ongoing litigation, particularly related to patent infringement claims.